Global H1N1 (Swine Flu) Vaccination Market, By Vaccine Type (Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccines, Intramuscular, and Toxoid), Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip, and Others) and End User (Hospitals, Clinics, and Others) – Industry Trends and Forecast to 2030.
H1N1 (Swine Flu) Vaccination Market Analysis and Size
The H1N1 flu, sometimes also known as swine flu, is a type of influenza A virus. It was often known as swine flu and was a new combination of influenza viruses that infect pigs, birds and humans. There have been severe cases of influenza in recent times. As per the World Health Organization (WHO), annually, around 3 to 5 million cases of severe illness and approximately 2,90,000 to 6,50,000 respiratory deaths are because of seasonal influenza. Also, increasing levels of respiratory ailments and immune deficient ailments due to the increasing elderly population has further caused huge growth opportunities for the H1N1 (swine flu) vaccination market.
Data Bridge Market Research analyses that the H1N1 (swine flu) vaccination market, which was USD 13.29 billion in 2022, would rise to USD 21.51 billion by 2030 and is expected to undergo a CAGR of 6.20% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
H1N1 (Swine Flu) Vaccination Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Vaccine Type (Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccines, Intramuscular, and Toxoid), Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip, and Others) and End User (Hospitals, Clinics, and Others)
|
|
Countries Covered
|
U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Mylan N.V. (U.S.), Baxter.(U.S.), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Virbac (France), Vetoquinol (France), Zoetis (U.S.), Novavax (U.S.)., Zydus Group (India)., Panacea Biotec (India), SINOVAC (China)., Abbott (U.S.), SEQIRUS (U.S.)., and Cipla Inc (India)
|
|
Market Opportunities
|
|
Market Definition
The H1N1 virus mainly causes swine flu. The H1N1 virus impedes the functioning of respiratory organs, which includes the nose, lungs, and throat. The H1N1 virus is a ribonucleic acid (RNA) virus belonging to the orthomyxoviridae family. The virus leads to high fever, body fatigue, headache, red, watery eyes, and general discomfort. The H1N1 virus also affects swine, birds, horses, and other animals apart from humans. The virus is transmissible and can spread from human to human.
Global H1N1 (Swine Flu) Vaccination Market Dynamics
Drivers
- Increasing Prevalence of Flu
Worldwide, the prevalence of flu is 3 to 5 million cases of severe illness and around 290, 000 to 650, 000 respiratory deaths. As per the Centers for Disease Control (CDC), around 8 percent of the U.S. population gets sick from the flu. In addition to this, around 200,000 people end up in the hospital every flu season. Thus, this increasing prevalence leads to the higher adoption of swine flu vaccination. This factor leads to the growth of the market.
- Growing Demand for Intramuscular Vaccines
There is a higher demand for intramuscular vaccines, which lead to market growth. The intramuscular vaccines segment holds a significant market share in the H1N1 vaccines market and is expected to show a trend during the forecast period. Increasing incidences of swine flu and the need for H1N1 vaccination is growing, and as a result, the intramuscular vaccines segment is also growing. Thus, this factor help in the market growth.
Opportunities
- Increasing Awareness of New Technologies in Vaccination
Numerous new technologies have the potential to alter the response activities of drugs in patients. These technologies involve the use of high-throughput approaches and whole-genome next-generation sequencing. These approaches can not only boost a new surveillance paradigm but also become major elements that are to be used in outbreak investigations. Developing techniques and approaches such as synthetic genomics, systems genetics, mathematical modeling, and systems biology are highly helpful. Thus, this factor boosts the market growth.
- Increasing Rate of Elderly Population
Another major factor boosting market growth is declining immunity among the geriatric population. The increasing elderly population with weakened immune systems makes them vulnerable to swine flu infection at a higher rate. Although H1N1 flu can affect anyone, immunocompromised people, such as cancer patients, are more vulnerable to swine flu and other infections. According to UN.org, the population above the age of 65 was around 703 million in 2019 and will double to around 1.5 billion by 2050 globally. Thus, this factor serves as a major factor that increases market growth.
Restraints/Challenges
- Side-Effects of H1N1 (swine flu) vaccination
Numerous effects are associated with H1N1 (swine flu) vaccination products. Local effects such as discomfort and local swelling at the vaccination site, reduced appetite and activity, sneezing, mild fever, "snotty nose," and mild coughing. Thus, this factor impedes market growth.
- Lack of Skilled Medical Individuals
There is a lack of skilled healthcare professionals that fail to deal with these patients who attain swine flu. Many of the viral diseases mimic each other and there is a very thin line of differentiation. Professionals fail to identify the diseases and sometimes lack a proper treatment. Thus, this factor leads to the market hindrance.
This H1N1 (swine flu) vaccination market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the H1N1 (swine flu) vaccination market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global H1N1 (Swine Flu) Vaccination Market Scope
The H1N1 (swine flu) vaccination market is segmented on the basis of vaccine type, type of brand, end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Vaccine Type
- Intranasal
- Conjugate
- Attenuated Vaccines
- Inactivated Vaccines
- Intramuscular
- Toxoid
Type of Brand
- Agripal
- Fiuarix
- Influgen
- Influvac
- Nasovac
- Vaxigrip
- Others
End User
- Hospitals
- Clinics
- Others
H1N1 (Swine Flu) Vaccination Market Regional Analysis/Insights
The H1N1 (swine flu) vaccination market is analyzed and market size insights and trends are provided by vaccine type, type of brand, end user as referenced above.
The countries covered in the H1N1 (swine flu) vaccination market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific is expected to grow during the forecast period the H1N1 (swine flu) vaccination market to the increasing awareness about the virus and growth in the infected population. Also, the developed healthcare infrastructure in this region leads to market growth.
In the forecast period, North America dominates the market due to the increasing expenditure for research and development proficiencies. Also, governments are taking numerous initiatives to avoid spreading diseases in people through numerous programs, vaccination campaigns and testing kits which is leading to market growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The H1N1 (swine flu) vaccination market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for H1N1 (swine flu) vaccination market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the H1N1 (swine flu) vaccination market. The data is available for historic period 2011-2021.
Competitive Landscape and H1N1 (Swine Flu) Vaccination Market Share Analysis
The H1N1 (swine flu) vaccination market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to H1N1 (swine flu) vaccination market.
Some of the major players operating in the H1N1 (swine flu) vaccination market are:
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Mylan N.V. (U.S.)
- Baxter.(U.S.)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Virbac (France)
- Vetoquinol (France)
- Zoetis (U.S.)
- Novavax (U.S.).
- Zydus Group (India).
- Panacea Biotec (India).
- SINOVAC (China).
- Abbott (U.S.)
- SEQIRUS (U.S.)
- Cipla Inc (India)
SKU-